Breaking News

OsoBio Names Quality VP

May 9, 2013

Lee oversaw validation, quality for Amgen expansion

David M. Lee has been appointed vice president of quality at OsoBio. Mr. Lee is responsible for overseeing all quality-related functions to ensure continued compliance with cGMP, including quality systems, quality control and manufacturing quality assurance. Mr. Lee has more than 20 years of professional experience managing quality operations and API and sterile manufacturing.
 
Prior to joining the company, he served as director of validation and quality at Amgen, where he managed all validation activities for a $1.2-billion site expansion. He also managed production operations for two of the company’s flagship drugs, Neupogen and Neulasta.
 
“David’s knowledge and expertise in quality operations will support OsoBio’s ongoing ability to deliver exceptional sterile pharmaceutical manufacturing products and service,” said Milton Boyer, president of OsoBio. “David has already proven to be a great asset to the OsoBio team and the clients we serve.”

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks